R&D Trends

Report: U.S. specialty pharma’s M&A focus shifts to pipelines and innovative products

Tuesday, June 14, 2016

Despite the ongoing challenges weighing on the U.S. specialty pharmaceutical sector, companies will steadily resume M&A with a more refined focus, said Moody’s Investors Service. The ratings agency said it expects acquisitive specialty companies will increase their focus on products with unmet medical need, companies with pipeline drugs and those providing geographic expansion.

[Read More]

Genomic Data Commons launches for data and clinical information sharing

Wednesday, June 8, 2016

The Genomic Data Commons (GDC), a unified data system that promotes sharing of genomic and clinical data between researchers, has launched. An initiative of the National Cancer Institute (NCI), the GDC will be a core component of the National Cancer Moonshot and the President’s Precision Medicine Initiative (PMI), and benefits from $70 million allocated to NCI to lead efforts in cancer genomics as part of PMI for Oncology.

[Read More]

Southwest Research, Texas Biomedical awarded $3.4M for Ebola countermeasure

Wednesday, June 8, 2016

Southwest Research Institute (SwRI) has announced a one-year, $3.4 million contract award from the Defense Threat Reduction Agency (DTRA) to combine two available medications and test the resulting combination drug therapy against the Ebola virus. SwRI is collaborating with Texas Biomedical Research Institute on this program. The award is a one-year contract with two additional option years.

[Read More]

Study: Global cancer treatment market hit $107B in 2015

Monday, June 6, 2016

More than 20 tumor types are being treated with one or more of the 70 new cancer treatments that have been launched in the past five years, with the sustained surge in innovative therapies driving the global oncology market to $107 billion in 2015. However, many of these drugs are not yet available to patients in most countries, and even when registered they may not be reimbursed under public insurance programs, according to a new study released by the IMS Institute for Healthcare Informatics.

[Read More]

Flatiron Health, FDA collaborate on cancer research

Wednesday, June 1, 2016

Flatiron Health and the FDA have signed a research collaboration agreement to determine how real-world evidence derived from de-identified, HIPAA-compliant patient data captured outside of clinical trials can provide new insights into the safety and effectiveness of emerging anti-cancer therapies such as immunotherapeutic agents.

[Read More]

Senate approves brain cancer research Bill

Tuesday, May 31, 2016

The Senate Committee on Appropriations has approved legislation that provides for the inclusion of “brain cancer” among the disorders eligible for study by the Department of Defense‘s (DoD) Peer Reviewed Cancer Research Program (PRCRP). This provision was included in the fiscal year 2017 Defense Appropriations Act, and mirrors action taken by the House on May 11 to add brain cancer to the PRCRP in its version of the Defense Appropriations Act.

[Read More]

NIHR invests $23.4M in pediatrics research

Tuesday, May 31, 2016

A significant number of children experience long-term health conditions. This group’s health needs have not previously been given the research priority that they deserve. The NIHR has invested £21 million ($23.4 million) in 35 new studies focusing on improving the health outcomes for children and young people.

[Read More]